The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome

Virology

Volumn 405, Issue 1, 2010, Pages 243-252

  Engel, Amber R ^a   Rumyantsev, Alexander A ^a,b   Maximova, Olga A ^a   Speicher, James M ^a   Heiss, Brian ^a   Murphy, Brian R ^a   Pletnev, Alexander G ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

Flavivirus; Live attenuated vaccine; Neurovirulence; Tick borne encephalitis virus

Indexed keywords

ALANINE; ARGININE; ASPARTIC ACID; NONSTRUCTURAL PROTEIN 5; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS ENVELOPE PROTEIN E315;

AMINO ACID SUBSTITUTION; ANIMAL TISSUE; ARTICLE; BRAIN; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DENGUE VIRUS; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOME; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SAFETY; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS REPLICATION; VIRUS VIRULENCE;

DENGUE VIRUS; FLAVIVIRUS; IXODIDA; MUS; TICK-BORNE ENCEPHALITIS VIRUS;

EID: 77955511170     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.06.014     Document Type: Article

References (41)

1. Andersson C.R., Vene S., Insulander M., Lindquist L., Lundkvist A., Gunther G. Vaccine failures after active immunisation against tick-borne encephalitis. Vaccine 2010, 28:2827-2831.
2. Ashour J., Laurent-Rolle M., Shi P.Y., Garcia-Sastre A. NS5 of dengue virus mediates STAT2 binding and degradation. J. Virol. 2009, 83:5408-5418.
3. Barrett A.D. Yellow fever vaccines. Biologicals 1997, 25:17-25.
4. Barrett P.N., Dorner F., Ehrlich H., Plotkin S.A. Tick-borne encephalitis virus vaccine. Vaccines 2004, 1039-1055. Saunders, Philadelphia. 4th ed. S. Plotkin, W. Orenstein (Eds.).
5. Bender A., Jager G., Scheuerer W., Feddersen B., Kaiser R., Pfister H.W. Two severe cases of tick-borne encephalitis despite complete active vaccination-the significance of neutralizing antibodies. J. Neurol. 2004, 251:353-354.
6. Blaney J.E., Johnson D.H., Firestone C.Y., Hanson C.T., Murphy B.R., Whitehead S.S. Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice. J. Virol. 2001, 75:9731-9740.
7. Blaney J.E., Johnson D.H., Manipon G.G., Firestone C.Y., Hanson C.T., Murphy B.R., Whitehead S.S. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 2002, 300:125-139.
8. Blaney J.E., Manipon G.G., Firestone C.Y., Johnson D.H., Hanson C.T., Murphy B.R., Whitehead S.S. Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine 2003, 21:4317-4327.
9. Blaney J.E., Speicher J., Hanson C.T., Sathe N.S., Whitehead S.S., Murphy B.R., Pletnev A.G. Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys. Vaccine 2008, 26:4150-4159.
10. Brauchli Y.B., Gittermann M., Michot M., Krahenbuhl S., Gnehm H.E. A fatal tick bite occurring during the course of tick-borne encephalitis vaccination. Pediatr. Infect. Dis. J. 2008, 27:363-365.
11. Diamond M.S. Mechanisms of evasion of the type I interferon antiviral response by flaviviruses. J. Interferon Cytokine Res. 2009, 29:521-530.
12. Durbin A.P., Karron R.A., Sun W., Vaughn D.W., Reynolds M.J., Perreault J.R., Thumar B., Men R., Lai C.J., Elkins W.R., Chanock R.M., Murphy B.R., Whitehead S.S. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am. J. Trop. Med. Hyg. 2001, 65:405-413.
13. Durbin A.P., McArthur J., Marron J.A., Blaney J.E., Thumar B., Wanionek K., Murphy B.R., Whitehead S.S. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum. Vaccin. 2006, 2:167-173.
14. Durbin A.P., McArthur J.H., Marron J.A., Blaney J.E., Thumar B., Wanionek K., Murphy B.R., Whitehead S.S. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum. Vaccin. 2006, 2:255-260.
15. Gritsun T.S., Lashkevich V.A., Gould E.A. Tick-borne encephalitis. Antiviral Res. 2003, 57:129-146.
16. Halstead S., Tsai T. Japanese encephalitis vaccines. Vaccine 2004, 919-958. Saunders, Philadelphia. 4th ed. S. Plotkin, W. Orenstein (Eds.).
17. Hanley K.A., Lee J.J., Blaney J.E., Murphy B.R., Whitehead S.S. Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes. J. Virol. 2002, 76:525-531.
18. Hurrelbrink R.J., McMinn P.C. Molecular determinants of virulence: the structural and functional basis for flavivirus attenuation. Adv. Virus Res. 2003, 60:1-42.
19. Jones M., Davidson A., Hibbert L., Gruenwald P., Schlaak J., Ball S., Foster G.R., Jacobs M. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J. Virol. 2005, 79:5414-5420.
20. Kleiter I., Steinbrecher A., Flugel D., Bogdahn U., Schulte-Mattler W. Autonomic involvement in tick-borne encephalitis (TBE): report of five cases. Eur. J. Med. Res. 2006, 11:261-265.
21. Kunze U. Tick-borne encephalitis-a European health challenge. Conference report of the 8th meeting of the International Scientific Working Group on Tick-borne Encephalitis (ISW TBE). Wien. Med. Wochenschr. 2006, 156:376-378.
22. Leonova G.N., Pavlenko E.V. Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human. Vaccine 2009, 27:2899-2904.
23. Lindenbach B., Thiel H., Rice C. Flaviviridae: the viruses and their replication. Fields Virology 2007, 1101-1152. Lippincott-Raven Publishers, Philadelphia. 5th ed. D. Knipe, P. Howley (Eds.).
24. Mandl C.W. Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis. Virus Res. 2005, 111:161-174.
25. Maximova O.A., Ward J.M., Asher D.M., St Claire M., Finneyfrock B.W., Speicher J.M., Murphy B.R., Pletnev A.G. Comparative neuropathogenesis and neurovirulence of attenuated flaviviruses in nonhuman primates. J. Virol. 2008, 82:5255-5268.
26. Mazzon M., Jones M., Davidson A., Chain B., Jacobs M. Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. J. Infect. Dis. 2009, 200:1261-1270.
27. Monath T.P. Yellow fever vaccine. Expert Rev. Vaccines. 2005, 4:553-574.
28. Park G.S., Morris K.L., Hallett R.G., Bloom M.E., Best S.M. Identification of residues critical for the interferon antagonist function of Langat virus NS5 reveals a role for the RNA-dependent RNA polymerase domain. J. Virol. 2007, 81:6936-6946.
29. Pletnev A.G., Men R. Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:1746-1751.
30. Pletnev A.G., Bray M., Huggins J., Lai C.J. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:10532-10536.
31. Pletnev A.G., Bray M., Lai C.J. Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice. J. Virol. 1993, 67:4956-4963.
32. Pletnev A.G., Swayne D.E., Speicher J., Rumyantsev A.A., Murphy B.R. Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 2006, 24:6392-6404.
33. Plisek S., Honegr K., Beran J. TBE infection in an incomplete immunized person at-risk who lives in a high-endemic area-impact on current recommendations for immunization of high-risk groups. Vaccine 2008, 26:301-304.
34. Randolph S.E. Tick-borne encephalitis incidence in Central and Eastern Europe: consequences of political transition. Microbes Infect. 2008, 10:209-216.
35. Reed L., Muench H. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 1938, 27:493-497.
36. Robertson S.J., Mitzel D.N., Taylor R.T., Best S.M., Bloom M.E. Tick-borne flaviviruses: dissecting host immune responses and virus countermeasures. Immunol. Res. 2009, 43:172-186.
37. Rumyantsev A.A., Chanock R.M., Murphy B.R., Pletnev A.G. Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys. Vaccine 2006, 24:133-143.
38. Rumyantsev A.A., Murphy B.R., Pletnev A.G. A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice. J. Virol. 2006, 80:1427-1439.
39. Suss J. Epidemiology and ecology of TBE relevant to the production of effective vaccines. Vaccine 2003, 21(Suppl 1):S19-S35.
40. Whitehead S.S., Falgout B., Hanley K.A., Blaney J.E., Markoff L., Murphy B.R. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys. J. Virol. 2003, 77:1653-1657.
41. Wright P.F., Ankrah S., Henderson S.E., Durbin A.P., Speicher J., Whitehead S.S., Murphy B.R., Pletnev A.G. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. Vaccine 2008, 26:882-890.